Goldman Sachs Group Inc Protagonist Therapeutics, Inc Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Goldman Sachs Group Inc holds 821,856 shares of PTGX stock, worth $33.4 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
821,856
Previous 590,761 39.12%
Holding current value
$33.4 Million
Previous $20.5 Million 80.44%
% of portfolio
0.01%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$33.72 - $47.33 $7.79 Million - $10.9 Million
231,095 Added 39.12%
821,856 $36.9 Million
Q2 2024

Aug 13, 2024
BUY
$24.66 - $34.8 $1.62 Million - $2.29 Million
65,721 Added 12.52%
590,761 $20.5 Million
Q1 2024

May 15, 2024
BUY
$21.79 - $32.15 $213,977 - $315,713
9,820 Added 1.91%
525,040 $15.2 Million
Q4 2023

Feb 13, 2024
BUY
$14.05 - $23.44 $674,638 - $1.13 Million
48,017 Added 10.28%
515,220 $11.8 Million
Q3 2023

May 14, 2024
SELL
$16.68 - $23.66 $800,923 - $1.14 Million
-48,017 Reduced 9.32%
467,203 $7.79 Million
Q3 2023

Nov 14, 2023
SELL
$16.68 - $23.66 $1.53 Million - $2.18 Million
-92,007 Reduced 16.45%
467,203 $7.79 Million
Q2 2023

May 14, 2024
BUY
$18.02 - $29.36 $1.8 Million - $2.93 Million
99,760 Added 21.71%
559,210 $15.4 Million
Q2 2023

Aug 14, 2023
BUY
$18.02 - $29.36 $1.8 Million - $2.93 Million
99,760 Added 21.71%
559,210 $15.4 Million
Q1 2023

May 14, 2024
SELL
$10.78 - $25.38 $1.7 Million - $3.99 Million
-157,274 Reduced 25.5%
459,450 $10.6 Million
Q1 2023

May 11, 2023
SELL
$10.78 - $25.38 $1.7 Million - $3.99 Million
-157,274 Reduced 25.5%
459,450 $10.6 Million
Q4 2022

May 14, 2024
SELL
$7.36 - $11.17 $1.03 Million - $1.57 Million
-140,355 Reduced 18.54%
616,724 $6.73 Million
Q4 2022

Feb 13, 2023
SELL
$7.36 - $11.17 $1.03 Million - $1.57 Million
-140,355 Reduced 18.54%
616,724 $6.73 Million
Q3 2022

May 14, 2024
BUY
$7.86 - $11.71 $983,781 - $1.47 Million
125,163 Added 19.81%
757,079 $6.38 Million
Q3 2022

Nov 10, 2022
BUY
$7.86 - $11.71 $983,781 - $1.47 Million
125,163 Added 19.81%
757,079 $6.38 Million
Q2 2022

May 14, 2024
BUY
$7.06 - $25.52 $823,873 - $2.98 Million
116,696 Added 22.65%
631,916 $5 Million
Q2 2022

Aug 15, 2022
BUY
$7.06 - $25.52 $2.02 Million - $7.29 Million
285,557 Added 82.45%
631,916 $5 Million
Q1 2022

May 16, 2022
BUY
$23.34 - $36.08 $5.2 Million - $8.04 Million
222,730 Added 180.16%
346,359 $8.2 Million
Q4 2021

Feb 14, 2022
SELL
$17.63 - $37.1 $5.28 Million - $11.1 Million
-299,566 Reduced 70.79%
123,629 $4.23 Million
Q3 2021

Nov 10, 2021
BUY
$12.95 - $49.69 $5.48 Million - $21 Million
423,195 New
423,195 $7.5 Million

Others Institutions Holding PTGX

# of Institutions
247
Shares Held
56.4M
Call Options Held
76.3K
Put Options Held
114K
View Full List

About Protagonist Therapeutics, Inc

PTGX Quotes by TradingView
  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email